Interferon-γ and nitric oxide production during Behçet uveitis: Immunomodulatory effect of interleukin-10

Journal of Interferon and Cytokine Research

Volumn 31, Issue 9, 2011, Pages 643-651

  Belguendouz, Houda ^a   Messaoudène, Djamel ^a   Lahmar, Karima ^a   Ahmedi, Laid ^a   Medjeber, Osama ^a   Hartani, Dahbia ^b   Lahlou Boukoffa, Ouidad ^c   Touil Boukoffa, Chafia ^a  

^a UNIVERSITY OF SCIENCES AND TECHNOLOGY HOUARI BOUMEDIENE   (Algeria)

^b CHU Mustapha   (Algeria)

^c Centre Hospitalier Universitaire de Annaba   (Algeria)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; MESSENGER RNA; NITRIC OXIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BEHCET DISEASE; BEHCET UVEITIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA EXTRACTION; SUPERNATANT; UVEITIS;

ADOLESCENT; ADULT; AGED; BEHCET SYNDROME; FEMALE; HUMANS; IMMUNOMODULATION; INTERFERON-GAMMA; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NITRIC OXIDE; RNA, MESSENGER; YOUNG ADULT;

EID: 80053018658     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2010.0148     Document Type: Article

References (70)

1. Afkarian M, Sedy JR, Yang J, Jacobson N G, Cereb N, Yang SY, Murphy TL, Murphy KM. 2002. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat Immunol 3(6):549-557. (Pubitemid 34662307)
2. Amri M, Aissa SA, Belguendouz H, Mezioug D, Touil-Boukoffa C. 2007. In vitro antihydatic action of IFN-gamma is dependent on the nitric oxide pathway. J Interferon Cytokine Res 27(9):781-787. (Pubitemid 47479862)
3. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk H-D, Döcke W-D. 1998. IL-10 is a key cytokine in psoriasis. proof of principle by IL-10 therapy: A new therapeutic approach. J Clin Invest 101(4):783-794. (Pubitemid 28096075)
4. Barnes CG, Yazici H. 1999. Behçet's syndrome. Rheumatology 38(12):1171-1174.
5. Beltran B, Mathur A, Duchen MR, Erusalimsky JD, Moncada S. 2000. The effect of nitric oxide on cell respiration: A key to understanding its role in cell survival or death. PNAS 97(26):14602-14607. (Pubitemid 32016622)
6. Borhani Haghighia A, Ittehadib H, Niksereshta AR, Rahmatic J, Ghaffari Poorjahromid S, Pourabbase B, Nazariniaf MA, Habibagahif Z, Fattahig MJ, Ghaderig A. 2009. CSF levels of cytokines in neuro-Behçet's disease. Clin Neurol Neurosurg 111:507-510.
7. Cañ ete JD, Celis R, Noordenbos T, Moll C, Gómez-Puerta JA, Pizcueta P, Palacin A, Tak PP, Sanmartí R and Baeten D. 2009. Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. Arthritis Res Ther 11(1):R17.
8. Dalghous AM, Freysdottir J, Fortune F. 2006. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol 35(6):472-475. (Pubitemid 47215715)
9. de Smet MD, Dayan M. 2000. Prospective determination of T-cell responses to S-antigen in Behçet's disease patients and controls. Invest Ophthalmol Vis Sci 41(11):3480-3484.
10. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A. 1995. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferoninduced cell death. Genes Dev 9(1):15-30.
11. Dennis VA, Jefferson A, Singh SR, Ganapamo F, Philipp MT. 2006. Interleukin-10 anti-inflammatory response to Borrelia burgdorferi, the agent of lyme disease: A possible role for suppressors of cytokine signaling 1 and 3. Infect Immun 74(10):5780-5789. (Pubitemid 44484564)
12. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. 1993. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen specific proliferation and cytokine production. J Immunol 150:353-360. (Pubitemid 23133609)
13. Ding A, Nathan CF, Stuehr DJ. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: Comparison of activating cytokines and evidence for independent production. J lmmunol 141:2407-2412.
14. Direskeneli H. 2001. Behçet's disease: Infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 60(11):996-1002. (Pubitemid 32990034)
15. Djeraba Z, Arroul-Lammali A, Medjeber O, Belguendouz H, Hartani D, Lahlou-Boukoffa OS, Touil-Boukoffa C. 2010. Nitric oxide, biomarker of experimental autoimmune uveitis induced by S antigen. J Fr Ophtalmol 33(10):693-700.
16. Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. 2001. Neutrophil activation in Behçet's disease. Clin Exp Rheumatol 19(5 Suppl 24):S19-S24.
17. Erdmann S, Ricken A, Hummitzsch K, Merkwitz C, Schliebe N, Gaunitz F, Strotmann R, Spanel-Borowski K. 2008. Inflammatory cytokines increase extracellular procathepsin D in permanent and primary endothelial cell cultures. Eur J Cell Biol 87(5):311-323.
18. Fiorentino DF, Bond MW, Mosmann TR. 1989. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170: 2081-2095.
19. García MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C, Esteban M. 2006. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 70(4):1032-1060. (Pubitemid 44958263)
20. Gow AJ, Farkouh CR, Munson DA, Posencheg MA, Ischiropoulos H. 2004. Biological significance of nitric oxide-mediated protein modifications. Am J Physiol Lung Cell Mol Physiol 287(2):L262-L268. (Pubitemid 38943907)
21. Guenane H, Hartani D, Chachoua L, Lahlou-Boukoffa OS, Mazari F, Touil-Boukoffa C. 2006. Production of Th1/Th2 cytokines and nitric oxide in Behçet's uveitis and idiopathic uveitis. J Fr Ophtalmol 29(2):146-152. (Pubitemid 43357239)
22. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. 2002. Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol 31(4): 205-210. (Pubitemid 34971876)
23. Hartani D, Belguendouz H, Guenane H, Chachoua L, Lahlou-Boukoffa OQ, Touil-Boukoffa C. 2006. Effect of nitrites and nitrates on bovine retina in vitro. J Fr Ophtalmol 9(1):32-36.
24. Hirohata S, Kikuchi K. 2003. Behçet's disease. Arthritis Res Ther 5(3):139-146.
25. Ilhan F, Demir T, Tü rkçü oǧ lu P, Turgut B, Demir N, Gödekmerdan A. 2008. Th1 polarization of the immune response in uveitis in Behçet's disease. Can J Ophthalmol 43(1):105-108. (Pubitemid 351269577)
26. Ito S, Ansari P, Sakatsume M, Dickensheets H, Vazquez N, Donnelley RP, Larner AC, Finbloom DS. 1999. Interleukin-10 inhibits expression of both interferon a- and interferon ginduced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93:1456-1463. (Pubitemid 29102470)
27. Jae Ka, Hyeong Gy, Hum C, Yeoung GP. 2006. Intraocular cytokine environment in active Behçet Uveitis. Am J Ophthalmol 142:429-434.
28. Kaneko F, Oyama N, Yanagihori H, Isogai E, Yokota K, Oguma K. 2008. The role of streptococcal hypersensitivity in the pathogenesis of Behçet's Disease. Eur J Dermatol 18(5):489-498.
29. Kolb JP. 2000. Mechanisms involved in the pro- and anti-apoptotic role of NO in human leukemia. Leukemia 14:1685-1694.
30. Lahmar-Belguendouz K, Belguendouz H, Hartani D, Lahlou-Boukoffa OS, Djeraba Z, Lammali A, Touil-Boukoffa C. 2009. Deleterious effects of stable nitric oxide derivatives, a uveitis inflammatory marker, on cultured bovine ocular layers. J Fr Ophtalmol 32(4):247-256.
31. Lee SB, Esteban M. 1994. The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis. Virology 199(2):491-496. (Pubitemid 24168991)
32. Li B, Yang P, Zhou H, Zhang Z, Xie C, Lin X, Huang X, Kijlstra A. 2003. T-bet expression is upregulated in active Behçet's disease. Br J Ophthalmol 87(10):1264-1267. (Pubitemid 37193919)
33. Li M-C, He S-H. 2004. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 10(5):620-625. (Pubitemid 38351523)
34. Liping D, Kijlstra A, Yang P. 2009. Immune Response Genes in Uveitis. Ocul Immunol Inflamm 17(4):249-256.
35. + monocytes enhances gamma interferon production in peripheral blood mononuclear cells from Mycobacterium avium subsp. paratuberculosis-Infected Goats. Clin Vaccine Immunol 16:1003-1011.
36. MacMicking J, Xie Q-W, Nathan C. 1997. Nitric oxide and macrophage function. Annu Rev Immunol 15:323-350. (Pubitemid 27169284)
37. Mege J-L, Dilsen N, Sanguedolce V. 1993. Overproduction of monocyte derived TNF, Interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20(9):1544-1549. (Pubitemid 24027329)
38. Mizuki N, Meguro A, Ota M, Ohno S, Shiota I, Kawagoe T, Ito N, Kera J, Okada E, Yatsu K, Song Y-W, Lee E-B, Kitaichi N, Namba K, Horie Y, Takeno M, Sugita S, Mochizuki M, Bahram S, Ishigatsubo Y, Inoko H. 2010. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet 42(8):703-707.
39. Mosmann TR, Schumacher JH, Fiorentino DF, Leverah J, Moore KW, Bond MW. 1990. Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th-2 specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunosorbent assay. J Immunol 145(9):2938-2945. (Pubitemid 20382564)
40. Nathan C. 1992. Nitric oxide a secretory product of mammalian cells. FASEB J 6(12):3051-3064.
41. Nathan CF, Hibbs JB. 1991. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 3: 65-70.
42. Niles JC, Wishnok JS, Tannenbaum SR. 2006. Peroxynitriteinduced oxidation and nitration products of guanine and 8-oxoguanine: Structures and mechanisms of product formation. Nitric Oxide 14(2):109-121. (Pubitemid 43165876)
43. Nussenblatt RB. 1997. Uveitis in Behçet's disease. Int Rev Immunol 14(1):67-79.
44. O'arra A, Vieira P. 2007. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol 7:425-428. (Pubitemid 46834852)
45. Ohno S, Kato F, Matsuda H, Fujii N, Minagawa T. 1982. Detection of gamma interferon in the sera of patients with Behc ȩt's disease. Infect Immun 36(1):202-208. (Pubitemid 12156425)
46. Pay S, Sximsxek I, Erdem H, Dinç A. 2007. Immunopathogenesis of Behçet's disease with special emphasize to the possible role of antigen presenting cells. Rheumatol Int 27(5):417-424. (Pubitemid 46294993)
47. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, Le JM, Yang B, Korman BD, Cakiris A, Aglar O, Emrence Z, Azakli H, Ustek D, Tugal-Tutkun I, Akman-Demir G, Chen W, Amos CI, Dizon MB, Akdag Kose A, Azizlerli G, Erer B, Brand OJ, Kaklamani VG, Kaklamanis P, Ben-Chetrit E, Stanford M, Fortune F, Ghabra M, Ollier WER, Cho Y-H, Bang D, O'SheaJ, Wallace GR, Gadina M, Kastner DL, Gü A. 2010. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated withBehçet's disease. Nat Genet 42(8):698-702.
48. Rico D, Vaquerizas JM, Dopazo H, Boscá L. 2007. Identification of conserved domains in the promoter regions of nitric oxide synthase 2: implications for the species-specific transcription and evolutionary differences. BMC Genomics 8:271-227.
49. Sxahýǹ Sx, Akoglu T, Direskeneli H, Sxen LS, Lawrence R. 1996a. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behcet's disease. Ann Rheum Dis 55(2):128-133.
50. Sxahín Sx, Lawrence R, Dtreskenelt H, Hamuryudan V, Yazici H, Akoglu T. 1996b. Monocyte activity in Behcet's disease. Br J Rheumatol 35(5):424-429.
51. Sakane T, Suzuki N, Nagafuchi H. 1997. Etiopathology of Behcet's disease: Immunological aspects. Yonsei Med J 38(6):350-358. (Pubitemid 128516394)
52. Saraiva M, O'Garra A. 2010. The regulation of IL-10 production by immune cells. Nat Rev Immunol 10(3):170-181.
53. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS, Jr. 1999. Interleukin- 10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274:31868-1874.
54. Slobodin G, Toukan Y, Rosner I, Rozenbaum M, Boulman N, Pavlotzky E, Kessel A, Toubi E. 2007. LPS-stimulated production of TNF-alpha by peripheral blood monocytes in patients with Behcet's disease. Clin Rheumatol 26(5):764-766.
55. Sun B, Sun SH, Chan CC, Caspi RR. 2000. Evaluation of in vivo cytokine expression in EAU-susceptible and resistant rats: A role for IL-10 in resistance? Exp Eye Res 70:493-502. (Pubitemid 30658891)
56. Suzuki N, Nara K, Suzuki T. 2006. Skewed Th1 responses caused by excessive expression of Txk, a member of the Tec family of tyrosine kinases, in patients with Behcet's disease. Clin Med Res 4(2):147-151. (Pubitemid 44047369)
57. Szabó C, Ischiropoulos H, Radi R. 2007. Peroxynitrite: Biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6(8):662-680. (Pubitemid 47207751)
58. Szabó C, Ohshima, H. 1997. DNA damage induced by peroxynitrite: Subsequent biological effects. Nitric Oxide 1(5): 373-385. (Pubitemid 28076545)
59. Szalay G, Sauter M, Hald J, Weinzierl A, Kandolf R, Klingel K. 2006. Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin- 10 disorders. Am J Pathol 169(6):2085-2093. (Pubitemid 351181968)
60. Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneoka H, Sakane T. 1995. Excessive function of peripheral blood neutrophils from patients with Behçet's disease and from HLA-B51 transgenic mice. Arthritis Rheum 38(3): 426-433.
61. Taylor SS, Haste NM, Ghosh G. 2005. PKR and elF2alpha: integration of kinase dimerization, activation, and substrate docking. Cell 122:823-825. (Pubitemid 41345196)
62. Touil-Boukoffa C, Bauvois B, Sancéau J, Hamrioui B, Wietzerbin J. 1998. Production of nitric oxide (NO) in human hydatidosis: Relationship between nitrite production and interferon-g levels. Biochimie 80(8-9):739-744. (Pubitemid 29497591)
63. Violi F, Marino R, Milite MT, Loffredo L. 1999. NO and its role in lipid peroxidation. Diabetes Metab Res Rev 15(4):283-288.
64. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. 1995. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 270: 9558-9563.
65. Yamamoto JH, Minami M, Inaba G, Masuda K, Mochizuki M. 1993. Cellular autoimmunity to retinal specific antigens in patients with Behçet's disease. Br J Ophthalmol 77(9):584-589. (Pubitemid 23281460)
66. Yamaoka K, Otsuka T, Niiro H, Nakashima H, Tanaka Y, Nagano S, Ogami E, Niho Y, Hamasaki N, Izuhara K. 1999. Selective DNA-binding activity of interleukin-10-stimulated STAT molecules in human monocytes. J Interferon Cytokine Res 19:679-685. (Pubitemid 29331322)
67. Yazici H, Fresko I, Yurdakul S. 2007. Behçet's syndrome: Disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 3(3):148-155. (Pubitemid 46416263)
68. Yurdakul S, Hamuryudan V, Yazici H. 2004. Behçet syndrome. Curr Opin Rheumatol 16(1):38-42.
69. Zhuang Y, Huang Z, Nishida J, Brown M, Zhang L, Huang H. 2009. A continuous T-bet expression is required to silence the interleukin-4-producing potential in T helper type 1 cells. Immunology 128(1):34-42.
70. Ziesché E, Bachmann M, Kleinert H, Pfeilschifter J, Mü hl H. 2007. The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. J Biol Chem 282(22):16006-16015. (Pubitemid 47100337)